- Home
- TGLS vs RNA Comparison
TGLS vs RNA Comparison
Compare TGLS & RNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TGLS | RNA |
|---|---|---|
| Founded | 1984 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electronic Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.3B |
| IPO Year | 2011 | 2025 |
Fundamental Metrics
Financial Performance| Metric | TGLS | RNA |
|---|---|---|
| Price | $42.20 | $14.95 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 20 |
| Target Price | $67.50 | ★ $69.26 |
| AVG Volume (30 Days) | 383.1K | ★ 2.8M |
| Earning Date | 05-29-2026 | 01-01-0001 |
| Dividend Yield | ★ 1.44% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 3.42 | N/A |
| Revenue | ★ $370,984,000.00 | N/A |
| Revenue This Year | $13.46 | $88.12 |
| Revenue Next Year | $9.77 | $18.11 |
| P/E Ratio | $12.23 | ★ N/A |
| Revenue Growth | ★ 17.98 | N/A |
| 52 Week Low | $41.73 | $13.06 |
| 52 Week High | $90.34 | $73.06 |
Technical Indicators
Market Signals| Indicator | TGLS | RNA |
|---|---|---|
| Relative Strength Index (RSI) | 27.33 | 4.14 |
| Support Level | N/A | $13.06 |
| Resistance Level | $54.59 | $72.52 |
| Average True Range (ATR) | 2.44 | 0.87 |
| MACD | -0.80 | -5.46 |
| Stochastic Oscillator | 11.76 | 1.78 |
Price Performance
Historical ComparisonAbout TGLS Tecnoglass Inc.
Tecnoglass Inc is a manufacturer of hi-spec architectural glass and windows for residential and commercial construction industries, operating through its direct and indirect subsidiaries. Its product offerings include tempered glass, laminated glass, thermo-acoustic glass, sliding windows, projecting windows, guillotine windows, sliding doors, loating facades, automatic doors, bathroom dividers, and commercial display windows, among others. The company has one operating segment, Architectural Glass and Windows, which is also its reporting segment. Geographically, the company generates maximum revenue from its customers in the United States, followed by Colombia, Panama, and other regions.
About RNA Avidity Biosciences Inc.
Avidity Biosciences Inc is a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, or AOCs. The company's pipeline currently has three programs in potentially registrational clinical trials: DM1, FSHD, and DMD. The segments includes following: Del-zota for DMD44, Del-desiran for DM1, Del-brax for FSHD.